

Steve Sisolak
Governor

Richard Whitley, MS
Director



**DEPARTMENT OF
HEALTH AND HUMAN SERVICES**
DIVISION OF HEALTH CARE FINANCING AND POLICY
Helping people. It's who we are and what we do.



Suzanne Bierman,
JD MPH
Administrator

**Notice of Meeting to Solicit Public Comments and Intent to Act Upon Amendments to the
Medicaid Services Manual (MSM)**

**Public Hearing July 26, 2022
Summary**

Date and Time of Meeting: July 26, 2022 at 10:12 AM

Name of Organization: State of Nevada, Department of Health and Human Services (DHHS), Division of Health Care Financing and Policy (DHCFP)

Place of Meeting: DHCFP
1100 E. William Street
First Floor Conference Room
Carson City, Nevada 89701

Teleconference and/or Microsoft Teams Attendees

(Note: This List May Not Include All Participants, Just Those Who Identified Themselves)

Gabriel Lither, Senior Deputy Attorney General (SDAG)	Lea Case, Belz & Case
Dr. Antonina Capurro, Deputy Administrator, DHCFP	Donalda Binstock, Clark County Social Services
Casey Angres, DHCFP	Alicia Roman, DHCFP
Kirsten Coulombe, DHCFP	Nicole R. Halcon, Centene Corporation
Michelyn Y. Domingo, Wellpoint	De
Carrie A. Greeley, Nevada Aging and Disability Services Division (ADSD)	Roxanne Coulter, Centene Corporation
Abigail Bailey, DHCFP	Angelica Velazquez Arias, DHCFP
Mark Du, DHCFP	Lawrence Henry, Fidelis-Rx
Torii Hayes, Olive Crest	Dawn Zito, Accessible Space, Inc
Kyril Plaskon, DHCFP	Rianna White, Fidelis-Rx
Kindra Berntson, DHCFP	Melody Hall-Ramirez, DHCFP
Antonio Gudino-Vargas, DHCFP	Tyler Shaw, FRPA
Shelle Sponseller, Accessible Space, Inc	Marcia Tinberg, DHCFP
Maria Reyes, Fidelis-Rx	David Olsen, DHCFP
Jerry Kappeler, Accessible Space, Inc	Yvonne Vestal, DHCFP

Introduction:

Casey Angres, Manager of Division Compliance, DHCFP, opened the Public Hearing introducing herself, Dr. Antonina Capurro, Deputy Administrator of DHCFP and Gabe Lither, SDAG.

Casey Angres – The notice for this public hearing was published on June 30, 2022, in accordance with Nevada Statute 422.2369.

1. **Public Comments:** No comments
2. **For possible action:** Discussion and adoption of changes to MSM Chapter 1200 – Prescribed Drugs

Kindra Berntson, Social Services Program Specialist for Pharmacy Services, DHCFP, presented the proposed revisions to MSM 1200 – Prescribed Drugs, based on recommendations approved at the April 28, 2022, Drug Utilization Review Board (DUR) Meeting.

The proposed changes include a title change to the Monoclonal Antibody Agents section to Respirator and Allergy Biologics Agents; Addition of new clinical criteria to Xolair® (omalizumab) for the indication of Nasal Polyps; The addition of new clinical criteria to Hetlioz® (tasimelteon) for indication of nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); The creation of a new section titled “Movement Disorder Agents,” which combines the existing Austedo® (Deutetrabenazine) and Ingrezza® (Valbenazine) clinical criteria into one section; the addition of new clinical criteria to Ingrezza® for the indication of Tardive Dyskinesia; and the addition of new prior authorization criteria for Vuity® (pilocarpine) 1.25% Ophthalmic Solution.

The following providers who prescribe, dispense, or administer these drugs may be affected by this change, including but not limited to the listed provider types on the agenda.

There is no financial impact on local government known.

The effective date of these changes is August 1, 2022.

At the conclusion of Kindra Berntson’s presentation, Casey Angres asked Dr. Antonina Capurro and Gabe Lither if they had any questions or comments, they had none.

Public Comment: No comments

Dr. Capurro approved the changes, pending spelling and grammar checks.

Casey Angres closed the Public Hearing for MSM Chapter 1200 – Prescribed Drugs.

3. **Adjournment**

There were no further comments and Casey Angres closed the public hearing at 10:14 AM.

****An Audio (CD) version of this meeting is available through the DHCFP Compliance office. For more detailed information on any of the handouts, submittals, testimony and or comments please contact documentcontrol@dncfp.nv.gov with any questions.***